Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:

• Morgan Stanley Global Healthcare Conference 2021 on Monday, Sept. 13, at 1:15 p.m. E.T.
• Cantor Fitzgerald Virtual Global Healthcare Conference on Monday, Sept. 27, at 1:20 p.m. E.T.

The presentations will be webcast live on the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact: Ian Estepan, 617-274-4052[email protected]

Media Contact: Tracy Sorrentino, 617-301-8566[email protected]

Source: Sarepta Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Last Chance to Join the Apeing Whitelist Before This Upcoming Crypto Coin Rivals Monero and Ethereum
• TTW Announces the Top 50 Travel Solution Cards in the World for 2026